Current Approach to Androgen Deprivation Therapy in Patients With Advanced Prostate Cancer  Axel Heidenreich  European Urology Supplements  Volume 9, Issue 11, Pages 776-781 (December 2010) DOI: 10.1016/j.eursup.2010.11.001 Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 1 Time trends in prostate-cancer risk stratification according to the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Reproduced with permission from Cooperberg et al [5]. European Urology Supplements 2010 9, 776-781DOI: (10.1016/j.eursup.2010.11.001) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier estimate of overall survival in patients receiving immediate or delayed hormonal therapy following radical prostatectomy. Reproduced with permission from Messing et al [7]. ADT=androgen-deprivation therapy; CI=confidence interval. European Urology Supplements 2010 9, 776-781DOI: (10.1016/j.eursup.2010.11.001) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier estimates of cancer-specific survival after surgery according to the number of positive nodes (two or fewer positive nodes vs more than two positive nodes; p<0.001). Reproduced with permission from Briganti et al [10]. European Urology Supplements 2010 9, 776-781DOI: (10.1016/j.eursup.2010.11.001) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 4 Overall survival according to prostate-specific antigen (PSA) at the end of a 7-mo induction with androgen deprivation in the Southwest Oncology Group 9346 Trial. Reproduced with permission from Hussain et al [21]. European Urology Supplements 2010 9, 776-781DOI: (10.1016/j.eursup.2010.11.001) Copyright © 2010 European Association of Urology Terms and Conditions